Multicenter, randomized, controlled trial of confocal laser endomicroscopy assessment of residual metaplasia after mucosal ablation or resection of GI neoplasia in Barrett's esophagus - 15/08/12
Reprint requests: Michael B. Wallace, MD, MPH, 4500 San Pablo Road, Jacksonville, FL 32224Résumé |
Background |
Endoscopic ablation is an accepted standard for neoplasia in Barrett's esophagus (BE). Eradication of all glandular mucosa in the distal esophagus cannot be reliably determined at endoscopy.
Objective |
To assess if use of probe-based confocal laser endomicroscopy (pCLE) in addition to high-definition white light (HDWL) could aid in determination of residual BE.
Design |
Prospective, multicenter, randomized, clinical trial.
Setting |
Academic medical centers.
Patients |
Patients with Barrett's esophagus undergoing ablation.
Intervention |
After an initial attempt at ablation, patients were followed-up either with HDWL endoscopy or HDWL plus pCLE, with treatment of residual metaplasia or neoplasia based on endoscopic findings and pCLE used to avoid overtreatment.
Main Outcome Measurements |
The proportion of optimally treated patients, defined as those with residual BE who were treated and had complete ablation plus those without BE who were not treated and had no evidence of disease at follow-up.
Results |
The study was halted at the planned interim analysis based on a priori criteria. After enrollment was halted, all patients who had been randomized were followed to study completion. Among the 119 patients with follow-up, there was no difference in the proportion of patients achieving optimal outcomes in the two groups (15/57, 26% for HDWL; 17/62, 27% with HDWL + pCLE). Other outcomes were similar in the two groups.
Limitations |
The study was closed after the interim analysis due to low conditional power resulting from lack of difference between groups as well as higher-than-expected residual Barrett's esophagus in both arms.
Conclusion |
This study yields no evidence that the addition of pCLE to HDWL imaging for detection of residual Barrett's esophagus or neoplasia can provide improved treatment. (Clinical trial registration number: NCT01032044.)
Le texte complet de cet article est disponible en PDF.Abbreviations : BE, GM, HDWL, HGD, HGN, IM, LGD, LGN, pCLE, RFA
Plan
| DISCLOSURE: Mauna Kea Technologies provided funding for this study to M. Wallace as a grant, I. Waxman and V. Konda as honoraria, and P. Sharma as research support. I. Waxman also received consulting fees from Olympus, and P. Sharma received research support from Olympus. No other financial relationships relevant to this publication were disclosed. |
|
| If you would like to chat with an author of this article, you may contact Dr Wallace at Wallace.michael@mayo.edu. |
Vol 76 - N° 3
P. 539 - septembre 2012 Retour au numéro
Article précédent
- Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett's esophagus
- Neil Gupta, Srinivas Gaddam, Sachin B. Wani, Ajay Bansal, Amit Rastogi, Prateek Sharma
- A prospective comparative study of optical coherence tomography and EUS for tumor staging of superficial esophageal squamous cell carcinoma
- Waku Hatta, Kaname Uno, Tomoyuki Koike, Katsunori Iijima, Naoki Asano, Akira Imatani, Tooru Shimosegawa
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?